TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change From Baseline in Lumbar Spine BMD Z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate (CR or R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 DNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Efficacy evaluation based on overall improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy evaluation based on severity by symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative live birth rate
Endpoint domain: Mortality/survival
Primary endpoint: proportion of modified Rankin Score of 0 to 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of systemic embolization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of cardiovascular death
Endpoint domain: Mortality/survival
Primary endpoint: Mobility Skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort Ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional and Hemodynamic Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lung damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of device-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Post-Concussion Symptom Inventory (PCSI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pharmacokinetic profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: First cycle dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Anatomical change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Estimated patient survival based on documentation (illness severity)
Endpoint domain: Mortality/survival
Primary endpoint: Friedreich Ataxia Rating Scale (FARS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in coagulation/inflammation parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self Care Power Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to exercise sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with eradicated Helicobacter infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Four Square Step Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Berg Balance Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Time Up & Go
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Hematological Complete Remission (HCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cases with discharge to ICU
Endpoint domain: Mortality/survival
Primary endpoint: Patients with resolution of digestive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety (Adverse Events and Device Malfunction)
Endpoint domain: Adverse events/effects
Primary endpoint: Placement success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Stent lumen patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Human Papillomavirus Genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Coughs Following Capsaicin Inhalation Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in blood biomarkers of neutrophil elastase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Nutrition optimization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change from baseline in intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Target Lesion Revascularization (TLR) at 12 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Composite of Device and/or Procedure Related Perioperative Death, Target Limb Major Amputation, and Target Vessel Revascularization at 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Knee Injury and Osteoarthritis Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of oral etoposide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Area under the plasma concentration time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hepatic fat content and abdominal fat ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Swanson, Nolan, and Pelham IV Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in electrical impedance measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory-Motor Integration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Level of creatinine in the urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Majeed functional outcome score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Completion rate of intervention sessions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Postoperative pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in insulin sensitivity and/or glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in left ventricular diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Fugl-Meyer Assessment (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Wolf Motor Function Test (WMFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Depressive Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Performance Characteristics and Usability measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a Physician's Global Assessment of Fingernails (PGA-F) of Clear or Minimal at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Troponin-T level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to discharge home
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Positive rate of anti-HPA antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Morbidity of NAIT
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal isometric leg extension strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Cognitively Impaired in EMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Subjects Depressed in EMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Geometric mean titer (GMT) of HAI antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of vaccine-associated serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of solicited local and systemic reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Generalized Self-Efficacy Scale (GSES)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of Illness Scale (AIS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analogue Scale of Pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delivery of concurrent chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Chromium serum ion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Chromium whole blood ion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cobalt serum ion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cobalt whole blood ion level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydroxytyrosol concentrations in biological fluids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of Alzheimer's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative malaria incidence
Endpoint domain: Mortality/survival
Primary endpoint: Diagnosis of muscle diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: sensitivity/specificity of LC U/S vs D-dimer in clinically unlikely DVT patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sensitivity/specificity of LC U/S plus D-dimer vs formal ultrasound in clinically likely DVT patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: brain lactate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody Titers Equal to or Above 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-polyribosylribitol Phosphate (Anti-PRP) Antibodies Equal to or Above 0.15 Micrograms Per Milliliter (µg/mL) and Equal to or Above 1 Micrograms Per Milliliter (µg/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) of Prasugrel Active Metabolite (Pras-AM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Platelet Inhibition as Measured by VerifyNow™P2Y12 (VN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) of Ankle Joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local efficacy of RFA treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blinded Readers Percent Agreement (PA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in leukocyte Myeloperoxidase (MPO) message
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in leukocyte Proteinase 3 (PR3) message
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of participants with an IES score > 37
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: p24 Antigen Production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Skeletal manifestations of Hypophosphatasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety and tolerability of Asfotase Alfa
Endpoint domain: Adverse events/effects
Primary endpoint: Averaged standing blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: % Time in Stage 2 Sleep at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pulse (heart rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in QT interval corrected for heart rate (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percent of Participants Alive and Without a Left Ventricular Lead-related Complication
Endpoint domain: Mortality/survival
Primary endpoint: Left Ventricular Bipolar Pacing Capture Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Numeric Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in MSSBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EVD-related infection
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of treatment discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Plasma Amprenavir (APV) AUC (0-tau[τ])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With the Indicated Treatment-emergent (TE) Grade 3/4 Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: blood homocysteine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean value of corrected QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myocardial Cellular Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Foot & Ankle Ability Measure (FAAM) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: American Orthopaedic Foot & Ankle score (AOFAs)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Short Form Health Survey - 12 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Absence of Persistent Atrial Tachyarrhythmias Relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: biomarker levels (UACR and BNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Simulated driving performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time of the maximum drug concentration in hours [Tmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed drug concentration in ng/mL [Cmax]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug concentration-time curve in ng*hr/mL [AUC(0-t)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the drug concentration-time curve from time zero to infinity in ng*hr/mL [AUC(0-inf)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of amenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients achieving biochemical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale (VAS) Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intravenous Morphine Equivalents During Post-anesthesia Care Unit (PACU) After Surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Painless Maximum Active Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Passive Forced Mouth Opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative recovery of radioactivity in excreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating tumor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quality of life (QOL) measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence and type of grade 2-5 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Family caregiver (FCG)-reported caregiving burden level
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: change in serum level of Uncarboxylated MGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate (SPR) for B/Victoria vaccine strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median Time to Cancer Recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients With Recurrence at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Tumor grade prediction accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With One or More Serious Adverse Event(s) (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Concentration (Cmax) of Olaratumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC) of Olaratumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery from Common Mental Disorder
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of the Syncope Prediction Algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the Syncope Prediction Algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Packed Red Blood Cells Transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Marginal Discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Delirium incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients improved on EDSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to walk 25 feet (TW25)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding cessation without recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Numeric Pain Intensity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Morphine Metabolic Equivalents (MME) Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/Absence of ICF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Functional Independence Measure (FIM)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of international Quality of Life Assessment Short Form -36 (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Growth of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent incidences of illness of infants
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Unintended extension of uterine incision
Endpoint domain: Adverse events/effects
Primary endpoint: PTSD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Panic symptoms scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CGI-S
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status